Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Non-Hodgkin 18Lymphoma 17Lymphoma, Follicular 15Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 10Lymphoma, Large B-Cell, Diffuse 9Multiple Myeloma 8Leukemia 6Waldenstrom Macroglobulinemia 5Hodgkin Disease 5Neoplasms 4Sezary Syndrome 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Mycosis Fungoides 3Burkitt Lymphoma 3Neoplasms, Plasma Cell 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Brain Neoplasms 2Advanced Solid Tumor 2

Interventions

ibrutinib 3Rituximab 3Lenalidomide 3spebrutinib 2fludarabine phosphate 2Cyclophosphamide 2tirabrutinib 1ricolinostat 1pembrolizumab 1ofatumumab 1navitoclax 1idelalisib 1fludarabine 1dinaciclib 1blinatumomab 1Rabeprazole 1Magnetic Resonance Imaging 1MLN 8237 1Leukapheresis 1KW-2478 1Itraconazole 1Immunotherapy, Adoptive 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Ciclopirox 1Blood Component Removal 1Biological Products 1Bendamustine Hydrochloride 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, B-Cell × Bendamustine Hydrochloride × Clear all
NCT01400685 2018-01-25

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Massachusetts General Hospital

Phase 1 Completed
34 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡